ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

ClinicalTrials.gov ID: NCT06526793

Public ClinicalTrials.gov record NCT06526793. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 20, 2026, 7:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Surovatamig (AZD0486) in Participants With Relapsed or Refractory (R/R) B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)

Study identification

NCT ID
NCT06526793
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
AstraZeneca
Industry
Enrollment
240 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 26, 2024
Primary completion
Mar 9, 2027
Completion
Jun 13, 2029
Last update posted
Feb 24, 2026

2024 – 2029

United States locations

U.S. sites
22
U.S. states
17
U.S. cities
22
Facility City State ZIP Site status
Research Site Phoenix Arizona 85054 Not yet recruiting
Research Site Duarte California 91010 Recruiting
Research Site Jacksonville Florida 32224 Not yet recruiting
Research Site Tampa Florida 33612 Recruiting
Research Site Chicago Illinois 60637 Not yet recruiting
Research Site Iowa City Iowa 52242 Not yet recruiting
Research Site Waukee Iowa 50263 Recruiting
Research Site Overland Park Kansas 66204 Withdrawn
Research Site Rochester Minnesota 55905 Recruiting
Research Site St Louis Missouri 63110 Withdrawn
Research Site New Brunswick New Jersey 08901 Withdrawn
Research Site New York New York 10016 Recruiting
Research Site Charlotte North Carolina 28204 Recruiting
Research Site Columbus Ohio 43210 Recruiting
Research Site Portland Oregon 97239 Recruiting
Research Site Philadelphia Pennsylvania 19104 Recruiting
Research Site Pittsburgh Pennsylvania 15232 Withdrawn
Research Site Nashville Tennessee 37203 Not yet recruiting
Research Site Austin Texas 78704 Not yet recruiting
Research Site Houston Texas 77030 Recruiting
Research Site San Antonio Texas 78229 Not yet recruiting
Research Site Milwaukee Wisconsin 53226 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 71 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06526793, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 24, 2026 · Synced Apr 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06526793 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →